ARTICLE | Finance
Genomics.com
January 4, 2000 8:00 AM UTC
Genomics stock continued their internet-like advances over the holidays, with investors starting to look down into the lower tier of companies for genomics plays that had not yet moved.
Leading the pack was Genome Therapeutics (GENE), which soared $11.188 (186 percent) to $17.188 on Christmas week on news of achieving a milestone in its asthma genomics deal with Schering-Plough and announcing a $118 million osteoporosis deal with Wyeth-Ayerst. GENE lost $1.063 to $16.125 last week. ...